Male Infertility – Pipeline Review, H1 2017 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Male
Infertility – Pipeline Review, H1 2017”
report to their

Male Infertility – Pipeline Review, H1 2017, provides comprehensive
information on the therapeutics under development for Male Infertility
(Male Health), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type. The guide covers the descriptive pharmacological action
of the therapeutics, its complete research and development history and
latest news and press releases.

The Male Infertility (Male Health) pipeline guide also reviews of key
players involved in therapeutic development for Male Infertility and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Phase II, Phase I, Preclinical,
Discovery and Unknown stages are 1, 2, 5, 2 and 1 respectively.
Similarly, the Universities portfolio in Preclinical and Discovery
stages comprises 1 and 1 molecules, respectively.

Male Infertility (Male Health) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Male Infertility – Overview
  3. Male Infertility – Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Male Infertility – Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Male Infertility – Companies Involved in Therapeutics Development
  • AlphaMab Co Ltd
  • Ferring International Center SA
  • Health Ever Bio-Tech Co Ltd
  • Navya Biologicals Pvt Ltd
  • PharmaEssentia Corp
  • TocopheRx Inc
  • Zydus Cadila Healthcare Ltd

For more information about this report visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Topics: Women’s
, Sexual
and Reproductive Health Drugs